Table 2 Clinical and pathological features of urine samples from asymptomatic controls and prostate cancer patients enrolled in this study (cohort #2)
Urine (cohort #2) | ||
|---|---|---|
Clinicopathological data | AC | PCa |
Patients, n | 32 | 87 |
Median age, years (range) | 58 (50–64) | 64 (47–75) |
Median PSA (ng/mL) (range) | n.a. | 8.80 (3.50–20.40) |
Pathological stage, n (%) | ||
pT2 | n.a. | 43 (49.43) |
pT3a | n.a. | 35 (40.23) |
pT3b | n.a. | 9 (10.34) |
Prognostic grade group, n (%) | ||
1 | n.a. | 34 (39.08) |
2 | n.a. | 39 (44.83) |
3 | n.a. | 7 (8.05) |
4 | n.a. | 5 (5.75) |
5 | n.a. | 2 (2.30) |